Zuberitamab plus bendamustine for untreated follicular lymphoma
Treatments studied
Part of Blood & lymphatic, Cancer, Immune system & allergy clinical trials.
This trial tests a combination of two drugs, zuberitamab and bendamustine, for people with a type of lymphoma called follicular lymphoma who have not had treatment before. The goal is to see if this combination is safe and effective, and then if keeping on one of the drugs alone helps keep the cancer from coming back.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have been diagnosed with follicular lymphoma (grades 1, 2, or 3a).
- You have not received any prior treatment for this lymphoma.
- Your disease is at stage II with a large tumor (7 cm or bigger), or at stage III or IV.
- You have at least one measurable tumor, and your disease is causing symptoms, affecting organs, or has other signs like bulky disease or low blood counts.
- You are generally well enough to carry out daily activities (ECOG score 0, 1, or 2) and your doctor expects you to live more than 6 months.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a combination of three drugs for people with previously untreated follicular lymphoma. The goal is to see if this combination helps control the lymphoma better.
This trial tests a combination of targeted therapy (zanubrutinib) and chemotherapy (G-CVP) for people with follicular lymphoma who have not had treatment before. It aims to see if this combination is safe and effective.
This study tests a new drug combination (using two targeted medicines and an immunotherapy drug) versus a standard chemotherapy combination for people with untreated follicular lymphoma. The goal is to see if the new combo works better with fewer side effects.
This trial tests a 3-drug combination (Zanubrutinib, Bendamustine, and Obinutuzumab) for people with advanced follicular lymphoma who have not had treatment before. The goal is to see if a fixed-duration treatment plan can improve outcomes.
This trial tests a combination of targeted therapy (zanubrutinib) with standard chemotherapy (G-CHOP) for people with untreated follicular lymphoma that is intermediate or high risk. The goal is to see if this combination can improve outcomes compared to standard care.
This trial tests a combination of three drugs (zanubrutinib, obinutuzumab, and lenalidomide) as a first treatment for follicular lymphoma. The goal is to see if this triple therapy works safely and effectively.
Hear when a new Follicular Lymphoma (FL) trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.